ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET FORECAST 2019-2028

  • You are here:
  • Home
  • Reports
  • ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET FORECAST 2019-2028

ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET FORECAST 2019-2028

The Asia Pacific immunosuppressant drugs market is estimated to register a CAGR of 5.51% during the forecast period. The growing demand for healthcare, an increasing number of hospitals in emerging countries, enhanced healthcare reforms, the developing R&D sector, and advanced technologies, are the factors propelling the market growth. Countries like China and India are projected to record the highest CAGR given their population base, surging R&D activities in the pharma sector, and demands for quick diagnosis of autoimmune diseases.

ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET FORECAST 2019-2028

Request free sample

The Asia Pacific immunosuppressant drugs market is estimated to register a CAGR of 5.51% during the forecast period. The growing demand for healthcare, an increasing number of hospitals in emerging countries, enhanced healthcare reforms, the developing R&D sector, and advanced technologies, are the factors propelling the market growth. Countries like China and India are projected to record the highest CAGR given their population base, surging R&D activities in the pharma sector, and demands for quick diagnosis of autoimmune diseases.
Asia Pacific Immunosuppressant Drugs Market

To learn more about this report, request a free sample copy

The countries analyzed in the Asia Pacific immunosuppressant drugs market for growth assessment are South Korea, Japan, China, Vietnam, Thailand, Indonesia, Australia & New Zealand, India, and the rest of Asia Pacific. In China, the pharmaceutical industry has been thriving since it became a part of the World Trade Organization. This makes the country an important player in the global pharmaceutical market. The research and development of immunosuppressants are listed as one of the national key scientific research projects by the government. The immunosuppressant market of China has many brands, joint ventures, along with brands of traditional Chinese medicine. In South Korea, the market growth is complemented by an experienced R&D manpower, strategic collaborations, strong passion for new drug development, and strong vision. A good number of organ transplants were registered in the country in 2018. The Vietnamese pharmaceutical industry has the scope for improved market prospects, given its low production costs and potential domestic market.

Cipla Limited (Cipla or ‘the company’) is a manufacturer of active pharmaceutical ingredients (APIs) and prescription drugs based in India. The product portfolio of the company includes Imusporin 100, along with 2000 products offered through many therapeutic categories in its facilities. The company’s operations are categorized under four strategic business units. The company has its headquarters in Mumbai, India.

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
    • MARKET DEFINITION
    •    KEY DRIVERS
      • INCREASE IN THE NUMBER OF AUTOIMMUNE DISORDERS
      • RISE IN ORGAN TRANSPLANTATION
      • GROWTH IN THE PHARMACEUTICAL INDUSTRY
    •    KEY RESTRAINTS
      • SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
      • LACK OF AWARENESS ABOUT ORGAN DONATION
  1. KEY ANALYTICS
    • KEY INVESTMENT INSIGHTS
    •    PORTER’S FIVE FORCE ANALYSIS
      • BUYER POWER
      • SUPPLIER POWER
      • SUBSTITUTION
      • NEW ENTRANTS
      • INDUSTRY RIVALRY
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
  2. MARKET BY DISTRIBUTION CHANNEL
    • HOSPITAL PHARMACIES
    • RETAIL PHARMACIES
    • ONLINE PHARMACIES
  3. MARKET BY END-USER
    • ORGAN TRANSPLANTATION
    • AUTOIMMUNE DISORDERS
    • OTHERS
  4. MARKET BY DRUG CLASS
    • CORTICOSTEROIDS
    • MONOCLONAL ANTIBODIES
    • CALCINEURIN INHIBITORS
    • MTOR INHIBITORS
    • OTHERS
  5. GEOGRAPHICAL ANALYSIS
    •    ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • SOUTH KOREA
      • INDONESIA
      • THAILAND
      • VIETNAM
      • AUSTRALIA & NEW ZEALAND
      • REST OF ASIA PACIFIC
  1. COMPANY PROFILES
    • ABBVIE INC
    • ALLERGAN PLC (ACQUIRED BY ABVIE INC)
    • ASTELLAS PHARMA INC
    • BRISTOL-MYERS SQUIBB COMPANY
    • CIPLA LTD
    • REDDY’S LABORATORIES LTD
    • F HOFFMANN-LA ROCHE AG
    • GLAXOSMITHKLINE PLC
    • INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE LTD)
    • JANSSEN PHARMACEUTICALS NV (JHONSON & JHONSON)
    • MYLAN NV
    • NOVARTIS INTERNATIONAL AG (SANDOZ)
    • PFIZER INC
    • SANOFI SA
    • VELOXIS PHARMACEUTICALS

TABLE LIST

TABLE 1: MARKET SNAPSHOT – IMMUNOSUPPRESSANT DRUGS

TABLE 2: SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS

TABLE 3: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES

TABLE 4: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 5: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 6: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 7: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 8: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 9: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 10: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 11: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

FIGURES LIST 

FIGURE 1: DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS

FIGURE 2: KEY INVESTMENT INSIGHTS

FIGURE 3: PORTER’S FIVE FORCE ANALYSIS

FIGURE 4: OPPORTUNITY MATRIX

FIGURE 5: VENDOR LANDSCAPE

FIGURE 6: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2019

FIGURE 7: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY HOSPITAL PHARMACIES, 2019-2028 (IN $ MILLION)

FIGURE 8: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY RETAIL PHARMACIES, 2019-2028 (IN $ MILLION)

FIGURE 9: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY ONLINE PHARMACIES, 2019-2028 (IN $ MILLION)

FIGURE 10: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2019

FIGURE 11: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TRANSPLANTATION, 2019-2028 (IN $ MILLION)

FIGURE 12: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY AUTOIMMUNE DISORDERS, 2019-2028 (IN $ MILLION)

FIGURE 13: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)

FIGURE 14: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY CLASS, IN 2019

FIGURE 15: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY CORTICOSTEROIDS, 2019-2028 (IN $ MILLION)

FIGURE 16: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)

FIGURE 17: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY CALCINEURIN INHIBITORS, 2019-2028 (IN $ MILLION)

FIGURE 18: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)

FIGURE 19: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)

FIGURE 20: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 21: CHINA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 22: JAPAN IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 23: INDIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 24: SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 25: INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 26: THAILAND IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 27: VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 28: AUSTRALIA & NEW ZEALAND IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 29: REST OF ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)

  1. GEOGRAPHICAL ANALYSIS
    •    ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • SOUTH KOREA
      • INDONESIA
      • THAILAND
      • VIETNAM
      • AUSTRALIA & NEW ZEALAND
      • REST OF ASIA PACIFIC
  1. MARKET BY DISTRIBUTION CHANNEL
    • HOSPITAL PHARMACIES
    • RETAIL PHARMACIES
    • ONLINE PHARMACIES
  2. MARKET BY END-USER
    • ORGAN TRANSPLANTATION
    • AUTOIMMUNE DISORDERS
    • OTHERS
  3. MARKET BY DRUG CLASS
    • CORTICOSTEROIDS
    • MONOCLONAL ANTIBODIES
    • CALCINEURIN INHIBITORS
    • MTOR INHIBITORS
    • OTHERS

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now